Olverembatinib
Phase II Clinical Trial
M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Phase II Clinical Trial cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid M.D. Anderson Cancer Center | Phase 2 | CCC |
Blinatumomab M.D. Anderson Cancer Center | Phase 2 | CCC |
METHOTREXATE M.D. Anderson Cancer Center | Phase 2 | CCC |
DEXAMETHASONE M.D. Anderson Cancer Center | Phase 2 | CCC |
(+)-VINCRISTINE M.D. Anderson Cancer Center | Phase 2 | CCC |
PREDNISONE TABLETS M.D. Anderson Cancer Center | Phase 2 | CCC |
Same molecule, other indications
Olverembatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
66 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →